MicroRNA (Shariqah, United Arab Emirates)最新文献

{"title":"The miR-195-3p is a Novel Prognostic Biomarker, Inhibiting Angiogenesis in Lung Adenocarcinoma.","authors":"Wei Zhou, Dafa Zhang, Jun Nie","doi":"10.2174/0122115366430893260506182415","DOIUrl":"https://doi.org/10.2174/0122115366430893260506182415","url":null,"abstract":"<p><strong>Introduction: </strong>In different kinds of tumors, miR-195-3p showed converse roles. How-ever, the role of miR-195-3p in lung adenocarcinoma (LUAD) remains unclear. To explore the prognostic role and potential underlying mechanisms of miR-195-3p in LUAD.</p><p><strong>Methods: </strong>In this study, we analyzed the correlation between the miR-195-3p expression level and clinicopathological features in LUAD based on the TCGA Database. The prognostic role of miR-195-3p was explored, and we then constructed a nomogram. The expression levels of miR-195-3p in LUAD tumor tissues and adjacent normal lung tissues were further determined by qRT-PCR in clinical samples. Finally, we explored the mechanisms by which miR-195-3p affects patient prognosis.</p><p><strong>Results: </strong>The results showed that miR-195-3p was expressed at decreased levels in LUAD tumor tissue. Furthermore, elevated miR-195-3p expression was associated with a better prognosis and served as an independent prognostic factor in LUAD. CD34 immunohistochemical staining showed that miR-195-3p expression was negatively correlated with microvessel density (MVD). Overexpression of miR-195-3p inhibited the migration and tube formation ability of HUVEC (Human Umbilical Vein Endothelial Cells).</p><p><strong>Discussion: </strong>Our findings demonstrate that miR-195-3p expression is significantly downregulated in LUAD tumor tissues compared to normal lung tissues, corroborating its tumor-suppressive role. The experiment suggests that this miRNA may exert its prognostic influence by modulating angiogenesis. However, this study still has several limitations that need to be addressed in future work.</p><p><strong>Conclusion: </strong>These findings indicate that miR-195-3p is a useful prognostic biomarker in LUAD, as well as a potential therapeutic target.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147976242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding TLR2 and BAX Gene Interactions on Maternal Immune Response in Frequent Spontaneous Abortions as Potential Biomarkers.","authors":"Kosar Babaei, Hossein Mozdarani, Misa Naghdipour Mirsadeghi, Seyed Reza Mirhafez, Seyedeh Elham Norollahi, Ebrahim Mirzajani, Mohsen Azimi-Nezhad, Ali Akbar Samadani","doi":"10.2174/0122115366436821260409070254","DOIUrl":"https://doi.org/10.2174/0122115366436821260409070254","url":null,"abstract":"<p><strong>Objective: </strong>Recurrent spontaneous abortion (RSA) represents a significant reproductive health challenge. The intricate balance of immune regulation at the maternal-fetal interface is crucial for maintaining pregnancy, involving complex interactions among multiple molecular pathways. In this way, TLR2 and the BAX have emerged as key players in immune modulation during pregnancy. This study examines the expression profiles of BAX and TLR2 in both maternal blood and fetal tissues across various trimesters, aiming to elucidate their potential role in RSA pathogenesis.</p><p><strong>Materials and methods: </strong>Blood and fetal tissue samples were collected from 120 participants (60 RSA cases and 60 controls) in the first and second trimesters. The gene expression of all specimens was measured using real-time PCR analysis. Correspondingly, Western blot analysis was used to evaluate the protein expression of all samples.</p><p><strong>Results: </strong>The p-values of BAX (0.0168) and TLR2 (0.0014) are much smaller than 0.05, indicating that the difference in these genes' expression between the two trimesters is statistically significant. BAX expression is substantially different between the first and second trimesters (p-value = 0.0168). There is a significant difference in TLR2 expression between the first and second trimesters (p-value = 0.0014). The p-values for both comparisons are extremely small (p<0.05), indicating that the difference in BAX and TLR2 expression between normal and RSA patients is highly significant. Notably, both BAX and TLR2 are significantly upregulated in RSA patients compared to normal blood, with statistically significant differences in expression. BAX shows a substantial decrease in expression between the first and second trimesters, indicating a downregulation of apoptotic processes as the pregnancy advances. Meanwhile, the protein expression of these genes had remarkable upregulation except for a decrease in the tissues of the embryos of the first trimester.</p><p><strong>Conclusion: </strong>The expression of BAX is highly upregulated in RSA patients compared to normal blood. The slight reduction in expression in the second trimester suggests that BAX, which is involved in apoptosis, may play a more prominent role in the early stages of pregnancy complications such as RSA. Its continued elevated expression in the second trimester indicates its sustained involvement in the pathophysiology of RSA.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147943156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The miR-29 Family in Virus-Associated Cancers: Mechanisms, Biomarkers, and Therapeutic Opportunities.","authors":"Mohammad Sediq Yousufzai, Bezhan Noori, Ramin Shahbahrami","doi":"10.2174/0122115366445113260406065701","DOIUrl":"https://doi.org/10.2174/0122115366445113260406065701","url":null,"abstract":"<p><p>The miR-29 family (miR-29a, miR-29b, and miR-29c) demonstrates context-depend-ent roles in cancers associated with oncogenic viruses (HPV, HBV/HCV, EBV, and HTLV-1), which collectively contribute to 15-20% of human malignancies. This comprehensive review ex-amines evidence that miR-29 primarily functions as a tumor suppressor by targeting DNMT3A, PTEN, and MCL-1, thereby regulating proliferation, apoptosis, and metastasis, though it exhibits paradoxical oncogenic activity in specific contexts, such as HBV-related Hepatocellular Carci-noma (HCC). Clinical data reveal virus-specific expression patterns: miR-29a is consistently downregulated in HPV-driven cervical tissues (progressively from CIN2/3 to invasive carci-noma), but circulating miR-29 members show diagnostic utility in viral hepatocellular carcinoma. The family displays dual roles in EBV pathogenesis, suppressing Burkitt's lymphoma through TCL1 inhibition yet promoting nasopharyngeal carcinoma metastasis via extracellular matrix dis-ruption. Current evidence supports miR-29's potential as a biomarker across multiple virus-asso-ciated cancers, with clinical utility in risk stratification and disease monitoring. While preclinical studies demonstrate that miR-29 restoration can inhibit tumor progression and reduce fibrosis in cell and animal models, significant challenges remain in delivery optimization and context-spe-cific application before clinical translation. Longitudinal validation studies and standardized de-tection methodologies are needed to establish the precise diagnostic and therapeutic value of miR-29 in viral oncology.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147942359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanomedicine for Alzheimer's Disease: Diagnostic and Therapeutic Progress.","authors":"Himani Pandey, Awaneet Kaur, Javed Khan, Anushka Sharma","doi":"10.2174/0122115366427696260203074113","DOIUrl":"https://doi.org/10.2174/0122115366427696260203074113","url":null,"abstract":"<p><p>The complex nature of the pathophysiology and limited treatment options of AD make it a huge challenge in healthcare. The recent developments in nanotechnology have given fresh hope for diagnosing and treating AD, which could serve as a way out of the existing problems. This review dwells on the role of nanotechnology in AD and its applications at its early stages through the development of nanosensors and boost imaging methods. Additionally, nanotechnology-driven therapeutic strategies are being investigated with nanoparticle-based drug delivery systems that aim to target the blood-brain barrier, among others. Current research innovations, clinical trials, and prospects highlight the transformative potential of nanotechnology in reshaping AD management. Ethical issues related to applying nanomedicine in neurodegenerative diseases, as well as fears about nanoparticles, are carefully analyzed herein. Finally, this review concludes with a synthesis of how nanotechnology has affected Alzheimer's Disease (AD) while emphasizing emerging trends and future directions toward advancing research on Alzheimer's Disease (AD). This comprehensive overview underscores the pivotal role of nanotechnology in revolutionizing AD prognosis and therapy, paving the way for personalized and effective treatment strategies.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Update: Exploring the Mechanisms and Clinical Significance of Amyloidosis-associated Neuropathy.","authors":"Krishana Kumar Sharma, Baljeet Kaur, Deepak Jain, Anjali Singh, Neelam Bhardwaj, Nishat Fatma","doi":"10.2174/0122115366414886251228035214","DOIUrl":"https://doi.org/10.2174/0122115366414886251228035214","url":null,"abstract":"<p><p>Amyloidosis encompasses a spectrum of disorders characterized by the extracellular accumulation of insoluble amyloid fibrils in various tissues, with peripheral neuropathy emerging as one of the most significant clinical manifestations. Peripheral sensory neurons are highly susceptible to amyloid-induced injury due to their long axonal projections and the relatively weaker neurovascular barrier of the dorsal root ganglia compared with the blood-brain and plasma-nerve barriers. Resulting nerve damage contributes to painful and disabling peripheral neuropathy, which affects millions worldwide. While hereditary amyloidosis polyneuropathies and type 2 diabetes are well-recognized conditions linked to amyloid deposition and neuropathy, similar pathogenic mechanisms may also be implicated in certain autoimmune and chronic metabolic disorders. A unifying histopathological feature across these diverse conditions is the deposition of amyloidogenic proteins. These fibrillar aggregates, composed of self-assembled peptides and proteins, disrupt tissue homeostasis, impair cellular function, and promote progressive nerve damage. Both inherited and acquired forms of amyloidosis are capable of triggering neuropathic complications, suggesting that amyloid-related mechanisms represent a convergent pathway in neuropathy of varied etiologies. In particular, type 2 diabetes mellitus stands out as a common condition in which amyloid accumulation significantly contributes to peripheral nerve injury. Collectively, these observations highlight the molecular and cellular parallels between different forms of amyloid-associated neuropathies and emphasize the need for deeper investigation into shared mechanisms that link protein aggregation with neuronal dysfunction.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance of Podoplanin in Oral Squamous Cell Carcinoma.","authors":"Deval Brajesh Dubey, Swati Agnihotri, Aniruddha Sen, Malti Kumari Maurya, Devanshi Brajesh Dubey","doi":"10.2174/0122115366434903260330072807","DOIUrl":"https://doi.org/10.2174/0122115366434903260330072807","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;About 80-90% of all oral cancers worldwide are Oral Squamous Cell Carcinomas (OSCCs), making them the most common type of oral malignancy. Due to its propensity for lymph node metastasis, lack of accurate prognostic indicators, and delayed diagnosis, OSCC remains linked to high morbidity and mortality despite advancements in surgical and therapeutic approaches. A mucin-type transmembrane glycoprotein, Podoplanin (PDPN), is well known as a lymphatic endothelial marker and plays roles in metastasis, Epithelial-Mesenchymal Transition (EMT), and tumor progression and growth. The goal of the current study was to determine whether podoplanin's immunohistochemistry expression in OSCC and its association with other clinicopathological parameters could serve as a biomarker for the course and outcome of the disease.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This observational study was conducted over one year in the Department of Pathology in collaboration with the Department of Surgical Oncology, King George's Medical University, Lucknow. A total of 110 histopathologically confirmed, treatment-naïve cases of OSCC were included. Detailed clinical and demographic data were collected. Tumour specimens were processed and evaluated as per the College of American Pathologists (CAP) guidelines. Immunohistochemistry was performed using anti-podoplanin (D2-40 clone) monoclonal antibody. The expression of podoplanin was assessed semi-quantitatively using the German Immunoreactive Score (IRS), which combines staining intensity and percentage of positive tumour cells.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The age of patients ranged from 23 to 75 years, with a mean of 45.3 years; the predominant age group was 31-40 years (35.5%). Males constituted 83.6% of the study population, and 89.1% had a history of tobacco, smoking, or alcohol use. The most commonly affected sites were the buccal mucosa (33.6%) and anterior tongue (30.9%). Most tumours were larger than 2.5 cm (58.2%) and exhibited a depth of invasion exceeding 10 mm (54.5%). Advanced pathological stage (Stage III-IV) was observed in 79.1% of cases, and 64.5% had nodal metastasis. Welldifferentiated tumours were most common (48.2%). Podoplanin expression ranged from weak (IRS 0-6) in 35.5% to strong (IRS &gt;6) in 64.5%. Strong podoplanin expression correlated positively with larger tumour size, moderate to well-differentiated tumours, and nodal metastasis (N1-N3), although no significant association was found with early vs. late pathological stage. Interestingly, T4-stage and poorly differentiated tumours showed a tendency toward weak expression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;The study confirms that strong podoplanin expression correlates with parameters indicative of tumour aggressiveness, including size, differentiation, and nodal involvement. These findings align with several prior studies, though the lack of significant association with pathological stage or overall survival underscores ","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147628676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"mRNA Vaccines: Development, Mechanisms and Advances in Delivery Systems.","authors":"Faranak Roudbari, Esmaeil Babaei, Rajinder Kaur, Raheleh Karimzadeh, Hewa Jalal Azeez","doi":"10.2174/0122115366415124260226141744","DOIUrl":"https://doi.org/10.2174/0122115366415124260226141744","url":null,"abstract":"<p><p>For more than over two decades, mRNA vaccines have been successfully administered and continues to be a promising platform for preventive and therapeutic uses. A key advantage of mRNA-based therapies over DNA-based approaches is that the mRNA molecule only needs to reach the cytoplasm for translation, bypassing the need for nuclear entry. Unlike pre-designed peptide vaccines, which may be restricted to specific MHC haplotypes, mRNA vaccines encode full-length antigens, allowing the host's cells to process and present a diverse array of epitopes suitable for a wide range of MHC haplotypes within a population. The binding of mRNA molecules to pattern recognition receptors enables them to be designed as self- adjuvants, a feature absent in peptide and protein-based vaccines. Since mRNA can encode and produce any protein, it enables the development of preventive and curative vaccinations to combat a range of illnesses, such as infections and cancer, as well as protein replacement therapies. The recent SARS-CoV-2 pandemic underscored the critical need for rapid vaccine platforms, a challenge effectively met by mRNA technology. Companies and research centers have created a variety of SARS-CoV-2 vaccines. These include older types of vaccines, such as those using viruses and proteins, as well as more advanced vaccines that utilize DNA and mRNA technology. This review outlines the recent advancements and advantages of mRNA vaccine technology, including how to design, synthesize, and deliver them to the target cells, as well as the immune system's response to these vaccines.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147623989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating miRNA Response to Kinesiological Intervention in Runners with Musculoskeletal Pain: A Pilot Study Integrating Expression and Network Analysis.","authors":"Maria Rosaria Tumolo, Egeria Scoditti, Antonella Bodini, Pierpaolo Mincarone, Carlo Giacomo Leo, Francesco Bagordo, Luca Bertone, Elisabetta De Matteis, Tiziana Grassi, Saverio Sabina","doi":"10.2174/0122115366430689251205145757","DOIUrl":"https://doi.org/10.2174/0122115366430689251205145757","url":null,"abstract":"<p><strong>Background: </strong>Musculoskeletal pain is highly prevalent among runners and often im-pairs performance and quality of life. Exercise-based interventions, such as kinesiology-guided programs, are increasingly used to promote recovery and prevent recurrence; however, individual responses vary widely. Circulating miRNA may serve as molecular biomarkers to elucidate un-derlying mechanisms and predict therapeutic outcomes. This study aimed to assess changes in circulating miRNAs in runners following a kinesiology-based intervention and to explore their potential involvement in pain-related biological processes.</p><p><strong>Methods: </strong>Seventeen long-distance runners with musculoskeletal pain underwent a six-week ki-nesiology-based intervention. Pain intensity and physical activity were assessed pre- and post-intervention. Plasma levels of four inflammation- and muscle-related miRNAs (hsa-let-7a-5p, hsa-miR-133b, hsa-miR-146a-5p, and hsa-miR-155-5p) were quantified using qRT-PCR. Bioin-formatic analyses were conducted to explore molecular networks involving the most responsive miRNAs.</p><p><strong>Results: </strong>Among the four analyzed miRNAs, three showed a downregulation after the interven-tion, with a statistically significant reduction in hsa-let-7a-5p (p = 0.035) and a near-significant decrease in hsa-miR-133b (p = 0.068). No significant associations were found between miRNA changes and pain remission in regression analysis. However, integrative network and pathway analyses revealed the involvement of hsa-let-7a-5p and hsa-miR-133b in molecular pathways re-lated to inflammation, tissue remodeling, and neuroimmune signaling.</p><p><strong>Discussion: </strong>The observed modulation of hsa-let-7a-5p and hsa-miR-133b suggests that these miRNAs may be sensitive to physiological changes induced by kinesiological intervention, po-tentially reflecting systemic adaptations rather than directly mediating pain remission. The lack of correlation with pain reduction may be due to the small sample size or the multifactorial nature of pain modulation. Nonetheless, the bioinformatic evidence highlights plausible biological mechanisms that merit further investigation.</p><p><strong>Conclusions: </strong>These findings suggest that hsa-let-7a-5p and hsa-miR-133b may reflect biological adaptations to functional recovery, even if they are not predictive of clinical outcomes. Further research is needed to validate their role in musculoskeletal rehabilitation and to assess their po-tential utility in guiding personalized exercise-based strategies.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of miR-214, miR-204, miR-25, miR-15a Expression with IL-33 and Malondialdehyde in Blood Samples from Patients with Alzheimer's Disease.","authors":"Haydar Sahib Almawashee, Mohammad Khalaj-Kondori, Mohammad Ali Hosseinpour Feizi, Reza Safaralizadeh","doi":"10.2174/0122115366411857251025004952","DOIUrl":"https://doi.org/10.2174/0122115366411857251025004952","url":null,"abstract":"<p><strong>Introduction: </strong>Alzheimer's disease (AD) is a late-onset neurodegenerative disease that affects older people. Deregulations of miRNAs play essential roles in AD pathogenesis; as a re-sult, they might be potential biomarkers for AD development, diagnosis, and treatment. This case-control study aimed to assess the expression of miR-214, miR-204, miR-15a, miR-25, and inves-tigate their correlations with the expression of IL-33, plasma level of Malondialdehyde (MDA), and Mini-Mental State Examination (MMSE) score of the AD patients.</p><p><strong>Methods: </strong>Blood samples were obtained from 125 participants, including 75 AD patients and 50 healthy controls. Plasma MDA level was assessed using the ZellBio ELISA kit. Total RNA was extracted from blood lymphocytes using RiboExTM (GeneAll), and expression levels of miRNAs and IL-33 were evaluated by qRT-PCR.</p><p><strong>Results: </strong>Results showed that miR-15a and miR-25, and IL-33 were downregulated in the pa-tients' group, but miR-214 and miR-204 were upregulated. Besides, the plasma level of MDA was significantly higher in the AD patients. A statistically significant negative correlation was observed between miR-15a and IL-33 expression. The MDA level showed a negative correlation with MMSE and a positive correlation with IL-33. Correlations between the miRNAs and MDA or MMSE scores were all non-significant. However, ROC curve analysis revealed that expres-sions of the studied miRNAs, IL-33, and the plasma level of MDA effectively differentiate AD patients from healthy controls.</p><p><strong>Discussion: </strong>Results showed that expression levels of miR-214, miR-204, miR-25, miR-15a, and IL-33 and MDA plasma levels are deregulated in AD patients, highlighting their potential relation with AD pathogenesis.</p><p><strong>Conclusion: </strong>Expression levels of the studied miRNAs and IL33, and plasma level of MDA might be considered as potential biomarkers for AD development and diagnosis.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146054237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to: Bone Marrow Mesenchymal Stem Cells Overexpressing MicroRNA-126 to Treat Critical Limb Ischemia.","authors":"Pegah Nammian, Seyedeh-Leili Asadi-Yousefabad, Seyyed Sajad Daneshi, Jafar Fallahi, Sahar Khajeh, Seyed Mohammad Bagher Tabei, Vahid Razban","doi":"10.2174/221153661501260611171549","DOIUrl":"https://doi.org/10.2174/221153661501260611171549","url":null,"abstract":"<p><p>In the published version of this article [1], an overlap discrepancy was identified in some of the slides in Fig. (7). This error was unintentional and occurred during the manuscript preparation stage by the authors. This correction does not affect the study's quantitative analyses, results, or conclusions. The authors apologize for this error and any inconvenience it may have caused. The original article can be found online at: https://www.eurekaselect.com/article/146623 The authors apologizes for this oversight and any inconvenience caused to the readers.</p>","PeriodicalId":38067,"journal":{"name":"MicroRNA (Shariqah, United Arab Emirates)","volume":"15 1","pages":"113"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148901136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}